Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.220 +0.010 (+0.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Nasdaq Tumbles 2%; Pliant Therapeutics Shares Spike Higher ↗
U.S. stocks traded lower midway through trading following the release of jobs report on Friday. 
Via Benzinga
News headline image
Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. 
Via Benzinga
News headline image
Why U.S. Stocks Are Trading Lower; AZZ Earnings And More ↗
U.S. stocks traded lower this morning as investors digested the recent jobs report for the month of June. 
Via Benzinga
News headline image
Why Are Pliant Therapeutics Shares Rallying Today? ↗
 
Via Benzinga
News headline image
Why Is Pliant Therapeutics (PLRX) Stock Soaring Today? ↗
Pliant Therapeutics (PLRX) stock is rocketing higher on Monday after revealing data from a Phase 2 clinical trial of PLN-74809. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Twitter Down By More Than 5%? 22 Stocks Moving In Monday's Pre-Market Session ↗
Gainers Inpixon (NASDAQ: INPX) rose 25.8% to $0.2305 in pre-market trading after gaining more than 22% on Friday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022 ↗
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Read Why Pliant Therapeutics Shares Are Soaring Today ↗
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 23.65% to $2.81 during Friday's regular session. As of 12:30 EST, BioLine Rx's stock is trading at a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 24, 2021 ↗
Upgrades For Aegon NV (NYSE:... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021 ↗
Upgrades Benchmark upgraded the previous rating for Devon Energy Corp (NYSE: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
News headline image
Mid-Day Market Update: Gold Drops 2%; Pliant Therapeutics Shares Jump ↗
Midway through trading Tuesday, the Dow traded down 0.76% to 35,098.84 while the NASDAQ rose 0.09% to 15,376.87. The S&P also fell, dropping 0.33% to 4,520.38. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
Why Pliant Therapeutics Stock Is Surging Today ↗
A positive phase 2 clinical trial readout was a positive step in the right direction for this biotech start-up. 
Via The Motley Fool
News headline image
45 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares jumped 32.6% to $4.2443. The company recently... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
News headline image
Pliant Stock Moves Higher On Positive Data From Pulmonary Fibrosis Trial ↗
Pliant Therapeutics Inc (NASDAQ: PLRX) stock is moving higher during the premarket session in reaction to interim results from a Phase 2a positron emission... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week ↗
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.